1. In Vivo
  2. >>Business Strategy

For New RSV Shots, ‘Vaccine Fatigue’ Could Be One Of The Biggest Barriers

 
• By Andrew McConaghie

Pfizer and GSK are expected to gain approval and launch in time for this year’s flu season, but must educate public and physicians  

COVID-19 vaccination

The US Food and Drug Administration is expected to shortly approve not one but two new vaccines – GlaxoSmithKline Pharmaceuticals Ltd.’s Arexvy and Pfizer Inc.’s Abrysvo – the first ever to combat respiratory syncytial virus in older adults.

Those decisions are expected in May, and for the first time offer healthcare providers the chance to prevent the serious symptoms caused by RSV, which can

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By David Wild

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By David Wild

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

More from In Vivo

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.

Rising Leaders 2025: Flagship’s Jacob Rubens On Building The Next Generation Of Biotech

 
• By David Wild

Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.